Leukemia Therapeutics Market (2010-2020) (Acute/Chronic Lymphocytic Leukemia & Acute/Chronic Myeloid Leukemia) Pipeline Forecast & Market Forecast in G8 Countries

Leukemia is the type of blood cancer and the ninth most common one in males. It accounts for almost 0.0148% of all the men and 0.009% of all the women worldwide. The leukemia market is segmented into four types; namely acute lymphocytic leukemia, chronic lymphocytic leukemia, acute myeloid leukemia, and chronic myeloid leukemia. The market was dominated by chronic myeloid leukemia in 2010. However, in 2020, the market is expected to be equally dominated by acute lymphocytic leukemia and chronic myeloid leukemia.

This report studies the market from 2010 to 2020 covering 29 major regimens and single drugs (off-patent and pipeline) for leukemia treatment. The growing population of leukemia is an impetus for the growth of the market. This market is expected to grow at a CAGR of 3.84% from 2015 to 2020. North America was the major contributor to this market; accounting for 61.95% of the total sales of leukemia drugs in 2010; whereas Gleevec was the major drug accounting for 55.48% of the total sales of leukemia drugs in 2010. Leukemia is still an area with high unmet need for early diagnosis and limited treatment options in this area.

The report studies 19 existing regimens and single drugs for leukemia market. Currently, there are about ten major drugs in pipeline for leukemia; which are expecting a market launch by 2012-2014; Talon Therapeutics Inc submitted new drug application to FDA for Marqibo in July 2011, leading to its market launch by 2012.

Quizartinib will be launched in the market in 2012 by Ambit Biosciences Inc (U.S.) on receiving fast track designation approval from the FDA in 2010. The drug is expected to be priced at $21,129 for patients who take them annually.

Players are implementing various growth strategies in the market to gain a competitive edge. New product launches, product pipelines, agreements and collaborations, clinical trials, and acquisitions were some of the major strategies adopted by the players from January 2008 to September 2011.

Pipeline drugs form a major growth strategy in the global leukemia therapeutics market accounting for 28% share between January 2008 and September 2011, followed by approvals with a 25% share, and agreements and collaborations with 24% share.

Novartis International AG, GlaxoSmithKline Pharmaceuticals Limited, Roche, Bristol-Myers Squibb, Genmab A/S, Celgene Corporation, and Biogen Idec rule the present market for leukemia drugs; whereas Ambit Bioscience & Pfizer are expected to capture major share of the market by 2020.

Scope of the report

This leukemia therapeutics market research report evaluates the leukemia drugs market with respect to the current and pipeline drugs and regimens. The report analyzes geography; forecasting revenue, and trends in each of the following submarkets:

• Chemotherapy regimens
  • Hyper-CVAD
  • CALGB 8811 regimen
  • Linker regimen
  • FC regimen
  • FCR regimen
  • DC regimen
  • VCD regimen
  • AVD regimen
• Chemotherapy drugs
  • Gleevec
  • Sprycel
  • Tasigna
  • Clolar
  • Nelarabine
  • Oncaspar
  • Fludara
  • Campath/MabCampath
  • Treanda
  • Arzerra
  • Cytarabine
• Pipeline drugs
  • Bosutinib
  • Omapro
  • Vidaza
  • Dacogen
  • Midostaurin
  • Vosaroxin
  • Quizartinib
  • GA101 / RG7159
  • Graspa
  • Marqibo

The geographies covered under the report are

• North America
  • U.S.
  • Canada
• Europe
  • U.K.
  • Germany
  • Italy
  • France
  • Spain
• Japan

Each section provides market data, market drivers, trends and opportunities, key players, and competitive outlook. This report also provides market tables for covering the sub-segments and micro-markets. Additionally, it makes ways for company profiles that cover all the sub-segments. The report has been made by keeping past trends, current happenings and future forecasts in consideration.

Customer Interested in this report also can view

• Acute Lymphocytic Leukemia Therapeutics Market (Pipeline Forecast & Market Forecast in G8 Countries) (2010 - 2020)

• Chronic Lymphocytic Leukemia Therapeutics Market in G8 Countries (2010 - 2020)

• Acute Myeloid Leukemia Therapeutics Market in G8 Countries (2010 - 2020)

TABLE OF CONTENTS    
    
1 INTRODUCTION   
  1.1 KEY TAKE-AWAYS   
  1.2 REPORT DESCRIPTION   
  1.3 MARKETS COVERED   
  1.4 STAKEHOLDERS   
  1.5 RESEARCH METHODOLOGY   
      1.5.1 MARKET SIZE   
      1.5.2 KEY DATA POINTS TAKEN FROM SECONDARY SOURCES   
      1.5.3 ASSUMPTIONS MADE FOR THIS REPORT   
    
2 EXECUTIVE SUMMARY   
  2.1 OVERVIEW OF THE MARKET   
    
3 MARKET OVERVIEW   
  3.1 DEFINING LEUKEMIA   
      3.1.1 DIAGNOSIS   
            3.1.1.1 Biopsy and bone marrow aspiration   
            3.1.1.2 Complete blood count (CBC) and differential   
            3.1.1.3 Philadelphia chromosome’s presence   
            3.1.1.4 Spinal tap (lumbar puncture) and cerebrospinal fluid (CSF) analysis   
            3.1.1.5 Immunophenotyping or phenotyping by flow cytometry   
            3.1.1.6 Polymerase chain reaction (PCR)   
      3.1.2 LEUKEMIA PREVALENCE   
      3.1.3 INCIDENCE & MORTALITY   
  3.2 TYPES OF LEUKEMIA   
      3.2.1 BASED ON DEVELOPMENTAL & PROGRESSION RATE   
            3.2.1.1 Chronic leukemia   
            3.2.1.2 Acute leukemia   
      3.2.2 BASED ON BONE MARROW CELLS AFFECTED   
            3.2.2.1 Lymphocytic (lymphoblastic) leukemia   
            3.2.2.2 Myelogenous (also called myeloid) leukemia   
      3.2.3 BASED ON DEVELOPMENT/PROGRESSION RATE & TYPE OF BONE MARROW CELLS AFFECTED   
            3.2.3.1 Acute Lymphocytic Leukemia (ALL)   
            3.2.3.2 Chronic Lymphocytic Leukemia (CLL)   
                    3.2.3.2.1 B-cell CLL   
                    3.2.3.2.2 T-cell CLL   
                    3.2.3.2.3 Hairy cell leukemia   
                    3.2.3.2.4 Large granular lymphocytic leukemia   
            3.2.3.3 Acute Myeloid Leukemia (AML)   
            3.2.3.4 Chronic Myeloid Leukemia (CML)   
  3.3 STAGES/PHASES OF LEUKEMIA   
      3.3.1 ACUTE LYMPHOCYTIC LEUKEMIA   
            3.3.1.1 Childhood ALL   
                    3.3.1.1.1 Standard (low) risk   
                    3.3.1.1.2 High risk   
                    3.3.1.1.3 Recurrent   
            3.3.1.2 Adult ALL   
                    3.3.1.2.1 Untreated adult ALL   
                    3.3.1.2.2 Adult ALL in remission   
                    3.3.1.2.3 Recurrent adult ALL   
      3.3.2 CHRONIC LYMPHOCYTIC LEUKEMIA   
            3.3.2.1 Stage 0   
            3.3.2.2 Stage I   
            3.3.2.3 Stage II   
            3.3.2.4 Stage III   
            3.3.2.5 Stage IV   
      3.3.3 ACUTE MYELOID LEUKEMIA   
            3.3.3.1 Childhood AML   
            3.3.3.2 Adult AML   
      3.3.4 CHRONIC MYELOGENOUS LEUKEMIA   
            3.3.4.1 Chronic stage   
            3.3.4.2 Accelerated stage   
            3.3.4.3 Blastic stage   
            3.3.4.4 Relapse   
  3.4 MARKET STRUCTURE   
      3.4.1.1 Key therapies   
              3.4.1.1.1 Chemotherapy   
              3.4.1.1.2 Stem cell/bone marrow transplant   
              3.4.1.1.3 Radiation therapy   
    
4 LEUKEMIA MARKET DYNAMICS   
  4.1 MARKET OVERVIEW   
  4.2 BURNING ISSUES   
  4.3 WINNING IMPERATIVES   
      4.3.1 BMS STRATEGY ON PRODUCT EDUCATION THROUGH ONLINE SERVICES   
  4.4 MARKET DYNAMICS   
      4.4.1 MARKET DRIVERS   
            4.4.1.1 Innovative therapies to drive the market for leukemia   
            4.4.1.2 Oncology is the largest therapeutic market with high unmet needs   
            4.4.1.3 Off-label prescribing drives market growth.   
      4.4.2 MARKET RESTRAINTS   
            4.4.2.1 Adverse events of treatment   
            4.4.2.2 Low production capability for efficient drugs   
      4.4.3 MARKET OPPORTUNITIES   
            4.4.3.1 Limited players in the market   
            4.4.3.2 Growing older male population   
            4.4.3.3 Leukemia’s underserved patient populations offer potential for market growth   
    
5 LEUKEMIA PRODUCT MARKET   
  5.1 MARKET OVERVIEW   
      5.1.1 GLEEVEC   
      5.1.2 SPRYCEL   
      5.1.3 TASIGNA   
      5.1.4 CAMPATH/MABCAMPATH   
      5.1.5 TREANDA   
      5.1.6 ARZERRA   
      5.1.7 FLUDARA   
      5.1.8 FCR REGIMEN   
      5.1.9 FC REGIMEN   
      5.1.10 HYPER-CVAD   
      5.1.11 CALGB 8811 REGIMEN   
      5.1.12 LINKER REGIMEN   
      5.1.13 NUCLEOSIDE METABOLIC INHIBITORS (CLOLAR + ARRANON)   
      5.1.14 ONCASPAR   
      5.1.15 DAUNORUBICIN + CYTARABINE (FOR INDUCTION)   
      5.1.16 CYTARABINE (FOR RELAPSE)   
      5.1.17 DAUNORUBICIN + CYTARABINE (FOR ELDERLY)   
      5.1.18 VCD REGIMEN (APL)   
      5.1.19 AVD REGIMEN (APL)   
    
6 LEUKEMIA DRUG PIPELINE (PHASE III)   
  6.1 PIPELINE DRUGS   
      6.1.1 BOSUTINIB   
      6.1.2 OMAPRO   
      6.1.3 GA101/RG7159   
      6.1.4 VIDAZA   
      6.1.5 DACOGEN   
      6.1.6 MIDOSTAURIN   
      6.1.7 VOSAROXIN   
      6.1.8 QUIZARTINIB   
      6.1.9 GRASPA   
      6.1.10 MARQIBO   
    
7 GEOGRAPHIC ANALYSIS   
  7.1 U.S.   
  7.2 CANADA   
  7.3 U.K.   
  7.4 GERMANY   
  7.5 FRANCE   
  7.6 ITALY   
  7.7 SPAIN   
  7.8 JAPAN   
    
8 COMPETITIVE LANDSCAPE   
  8.1 INTRODUCTION   
    
9 COMPANY PROFILES   
  9.1 AMBIT BIOSCIENCES CORPORATION   
      9.1.1 OVERVIEW   
      9.1.2 FINANCIALS   
      9.1.3 PRODUCTS & SERVICES   
      9.1.4 STRATEGY   
      9.1.5 DEVELOPMENTS   
  9.2 ARIAD PHARMACEUTICALS INC   
      9.2.1 OVERVIEW   
      9.2.2 FINANCIALS   
      9.2.3 PRODUCTS & SERVICES   
      9.2.4 DEVELOPMENTS   
  9.3 BIOGEN IDEC INC.   
      9.3.1 OVERVIEW   
      9.3.2 FINANCIALS   
      9.3.3 PRODUCTS & SERVICES   
      9.3.4 DEVELOPMENTS   
  9.4 BRISTOL-MYERS SQUIBB   
      9.4.1 OVERVIEW   
      9.4.2 FINANCIALS   
      9.4.3 PRODUCTS & SERVICES   
      9.4.4 STRATEGY   
      9.4.5 DEVELOPMENTS   
  9.5 CELGENE CORPORATION   
      9.5.1 OVERVIEW   
      9.5.2 FINANCIALS   
      9.5.3 PRODUCTS & SERVICES   
      9.5.4 STRATEGY   
      9.5.5 DEVELOPMENTS   
  9.6 CEPHALON INC   
      9.6.1 OVERVIEW   
      9.6.2 FINANCIALS   
      9.6.3 PRODUCTS & SERVICES   
      9.6.4 STRATEGY   
      9.6.5 DEVELOPMENTS   
  9.7 CLAVIS PHARMA ASA   
      9.7.1 OVERVIEW   
      9.7.2 FINANCIALS   
      9.7.3 PRODUCTS & SERVICES   
      9.7.4 STRATEGY   
      9.7.5 DEVELOPMENTS   
  9.8 EISAI CO. LTD.   
      9.8.1 OVERVIEW   
      9.8.2 FINANCIALS   
      9.8.3 PRODUCTS & SERVICES   
      9.8.4 STRATEGY   
      9.8.5 DEVELOPMENTS   
  9.9 ERYTECH PHARMA   
      9.9.1 OVERVIEW   
      9.9.2 FINANCIALS   
      9.9.3 PRODUCTS & SERVICES   
      9.9.4 STRATEGY   
      9.9.5 DEVELOPMENTS   
  9.10 GENMAB A/S   
      9.10.1 OVERVIEW   
      9.10.2 FINANCIALS   
      9.10.3 PRODUCTS & SERVICES   
      9.10.4 STRATEGY   
      9.10.5 DEVELOPMENTS   
  9.11 GENZYME CORPORATION   
      9.11.1 OVERVIEW   
      9.11.2 FINANCIALS   
      9.11.3 PRODUCTS & SERVICES   
      9.11.4 STRATEGY   
      9.11.5 DEVELOPMENTS   
  9.12 GLAXOSMITHKLINE PLC   
      9.12.1 OVERVIEW   
      9.12.2 FINANCIALS   
      9.12.3 PRODUCTS & SERVICES   
      9.12.4 STRATEGY   
      9.12.5 DEVELOPMENTS   
  9.13 NOVARTIS INTERNATIONAL AG   
      9.13.1 OVERVIEW   
      9.13.2 FINANCIALS   
      9.13.3 PRODUCTS & SERVICES   
      9.13.4 STRATEGY   
      9.13.5 DEVELOPMENTS   
  9.14 PFIZER INC   
      9.14.1 OVERVIEW   
      9.14.2 FINANCIALS   
      9.14.3 PRODUCTS & SERVICES   
      9.14.4 STRATEGY   
      9.14.5 DEVELOPMENTS   
  9.15 ROCHE HOLDING AG   
      9.15.1 OVERVIEW   
      9.15.2 FINANCIALS   
      9.15.3 PRODUCTS & SERVICES   
      9.15.4 STRATEGY   
      9.15.5 DEVELOPMENTS   
  9.16 SUNESIS PHARMACEUTICALS INC   
      9.16.1 OVERVIEW   
      9.16.2 FINANCIALS   
      9.16.3 PRODUCTS & SERVICES   
      9.16.4 STRATEGY   
      9.16.5 DEVELOPMENTS   
  9.17 TALON THERAPEUTICS INC   
      9.17.1 OVERVIEW   
      9.17.2 FINANCIALS   
      9.17.3 PRODUCTS & SERVICES   
      9.17.4 STRATEGY   
      9.17.5 DEVELOPMENTS   
    
     
LIST OF TABLES    
    
TABLE 1 YEARLY COST OF DRUGS IN NORTH AMERICA & JAPAN, 2011 ($)   
TABLE 2 YEARLY COST OF DRUGS IN EUROPEAN COUNTRIES, 2011 ($)   
TABLE 3 DOSAGE PATTERN OF DRUGS   
TABLE 4 LEUKEMIA DRUGS MARKET REVENUE, BY REGIMENS/DRUGS, 2008 - 2020 ($MILLION)   
TABLE 5 ACUTE LYMPHOCYTIC LEUKEMIA DRUGS – PATENT STATUS   
TABLE 6 CHRONIC LYMPHOCYTIC LEUKEMIA DRUGS – PATENT STATUS   
TABLE 7 CHRONIC MYELOID LEUKEMIA DRUGS – PATENT STATUS   
TABLE 8 ACUTE LYMPHOCYTIC LEUKEMIA DRUGS MARKET REVENUE, BY TYPES, 2008 – 2020 ($MILLION)   
TABLE 9 CHRONIC LYMPHOCYTIC LEUKEMIA DRUGS MARKET REVENUE, BY TYPES, 2008 – 2020 ($MILLION)   
TABLE 10 ACUTE MYELOID LEUKEMIA DRUGS MARKET REVENUE, BY TYPES, 2008 – 2020 ($MILLION)   
TABLE 11 CHRONIC MYELOID LEUKEMIA DRUGS MARKET REVENUE, BY TYPES, 2008 – 2020 ($MILLION)   
TABLE 12 AGED MALE POPULATION GROWTH, 2010 – 2025 (THOUSAND)   
TABLE 13 LEUKEMIA DRUG/REGIMENS MARKET REVENUE, 2008 – 2020 ($MILLION)   
TABLE 14 LEUKEMIA DRUGS (GLEEVEC) MARKET REVENUE, BY COUNTRY, 2008 – 2020 ($MILLION)   
TABLE 15 LEUKEMIA DRUGS (SPRYCEL) MARKET REVENUE, BY COUNTRY, 2008 – 2020 ($MILLION)   
TABLE 16 LEUKEMIA DRUGS (TASIGNA) MARKET REVENUE, BY COUNTRY, 2008 – 2020 ($MILLION)   
TABLE 17 LEUKEMIA DRUGS (CAMPATH) MARKET REVENUE, BY COUNTRY, 2008 – 2020 ($MILLION)   
TABLE 18 LEUKEMIA DRUGS (TREANDA) MARKET REVENUE, BY COUNTRY, 2008 – 2020 ($MILLION)   
TABLE 19 LEUKEMIA DRUGS (ARZERRA) MARKET REVENUE, BY COUNTRY, 2008 – 2020 ($MILLION)   
TABLE 20 LEUKEMIA DRUGS (FLUDARA) MARKET REVENUE, BY COUNTRY, 2008 – 2020 ($MILLION)   
TABLE 21 LEUKEMIA REGIMEN (FCR) MARKET REVENUE, BY COUNTRY, 2008 – 2020 ($MILLION)   
TABLE 22 LEUKEMIA REGIMEN (FC) MARKET REVENUE, BY COUNTRY, 2008 – 2020 ($MILLION)   
TABLE 23 LEUKEMIA REGIMEN (HYPER-CVAD) MARKET REVENUE, BY COUNTRY, 2008 – 2020 ($MILLION)   
TABLE 24 LEUKEMIA REGIMEN (CALGB 8811) MARKET REVENUE, BY COUNTRY, 2008 – 2020 ($MILLION)   
TABLE 25 LEUKEMIA DRUGS (LINKER REGIMEN) MARKET REVENUE, BY COUNTRY, 2008 – 2020 ($MILLION)   
TABLE 26 LEUKEMIA DRUG CLASS (NUCLEOSIDE METABOLIC INHIBITORS) MARKET REVENUE, BY COUNTRY, 2008 – 2020  ($MILLION)   
TABLE 27 LEUKEMIA DRUGS (ONCASPAR) MARKET REVENUE, BY COUNTRY, 2008 – 2020 ($MILLION)   
TABLE 28 LEUKEMIA DC REGIMEN MARKET REVENUE, BY COUNTRY, 2008 – 2020 ($MILLION)   
TABLE 29 LEUKEMIA CYTARABINE MARKET REVENUE, BY COUNTRY, 2008 – 2020 ($MILLION)   
TABLE 30 LEUKEMIA DC REGIMEN FOR ELEDERLY MARKET REVENUE, BY COUNTRY, 2008 – 2020 ($MILLION)   
TABLE 31 LEUKEMIA VCD REGIMEN MARKET REVENUE, BY COUNTRY, 2008 – 2020 ($MILLION)   
TABLE 32 LEUKEMIA AVD REGIMEN MARKET REVENUE, BY COUNTRY, 2008 – 2020 ($MILLION)   
TABLE 33 LEUKEMIA DRUGS – PIPELINE (BOSUTINIB) MARKET REVENUE, BY COUNTRY, 2015 – 2020 ($MILLION)   
TABLE 34 LEUKEMIA DRUGS – PIPELINE (OMAPRO) MARKET REVENUE, BY COUNTRY, 2015 – 2020 ($MILLION)   
TABLE 35 LEUKEMIA DRUGS – PIPELINE (GA 101/RG 7159) MARKET REVENUE, BY COUNTRY, 2015 – 2020 ($MILLION)   
TABLE 36 LEUKEMIA DRUGS – PIPELINE (VIDAZA) MARKET REVENUE, BY COUNTRY, 2015 – 2020 ($MILLION)   
TABLE 37 LEUKEMIA DRUGS – PIPELINE (DACOGEN) MARKET REVENUE, BY COUNTRY, 2015 – 2020 ($MILLION)   
TABLE 38 LEUKEMIA DRUGS – PIPELINE (MIDOSTAURIN) MARKET REVENUE, BY COUNTRY, 2015 – 2020 ($MILLION)   
TABLE 39 LEUKEMIA DRUGS – PIPELINE (VOSAROXIN) MARKET REVENUE, BY COUNTRY, 2015 – 2020 ($MILLION)   
TABLE 40 LEUKEMIA DRUGS – PIPELINE (QUIZARTINIB) MARKET REVENUE, BY COUNTRY, 2015 – 2020 ($MILLION)   
TABLE 41 LEUKEMIA DRUGS – PIPELINE (GRASPA) MARKET REVENUE, BY COUNTRY, 2015 – 2020 ($MILLION)   
TABLE 42 LEUKEMIA DRUGS – PIPELINE (MARQIBO) MARKET REVENUE, BY COUNTRY, 2015 – 2020 ($MILLION)   
TABLE 43 SEER STATISTICS FOR LEUKEMIA (ESTIMATED) IN U.S., 2011   
TABLE 44 U.S: LEUKEMIA DRUGS MARKET REVENUE, BY DRUGS/REGIMENS, 2008 – 2020 ($MILLION)   
TABLE 45 U.S: LEUKEMIA DRUGS – PIPELINE MARKET REVENUE, BY DRUGS, 2008 – 2020 ($MILLION)   
TABLE 46 CANADA: LEUKEMIA DRUGS MARKET REVENUE, BY DRUGS/REGIMENS, 2008 – 2020 ($MILLION)   
TABLE 47 CANADA: LEUKEMIA DRUGS – PIPELINE MARKET REVENUE, BY DRUGS, 2015 – 2020 ($MILLION)   
TABLE 48 U.K: INCIDENCE BY GENDER & TYPE OF LEUKEMIA, 2010   
TABLE 49 U.K: LEUKEMIA DRUGS MARKET REVENUE, BY DRUGS/REGIMENS, 2008 – 2020 ($MILLION)   
TABLE 50 U.K: LEUKEMIA DRUGS – PIPELINE MARKET REVENUE, BY DRUGS, 2015 – 2020 ($MILLION)   
TABLE 51 GERMANY: LEUKEMIA DRUGS MARKET REVENUE, BY DRUGS/REGIMENS, 2008 – 2020 ($MILLION)   
TABLE 52 GERMANY: LEUKEMIA DRUGS – PIPELINE MARKET REVENUE, BY DRUGS, 2015 – 2020 ($MILLION)   
TABLE 53 FRANCE: LEUKEMIA DRUGS MARKET REVENUE, BY DRUGS/REGIMENS, 2008 – 2020 ($MILLION)   
TABLE 54 FRANCE: LEUKEMIA DRUGS – PIPELINE MARKET REVENUE, BY DRUGS, 2015 – 2020 ($MILLION)   
TABLE 55 ITALY: LEUKEMIA DRUGS MARKET REVENUE, BY DRUGS/REGIMENS, 2008 – 2020 ($MILLION)   
TABLE 56 ITALY: LEUKEMIA DRUGS – PIPELINE MARKET REVENUE, BY DRUGS, 2015 – 2020 ($MILLION)   
TABLE 57 SPAIN: LEUKEMIA DRUGS MARKET REVENUE, BY DRUGS/REGIMENS, 2008 – 2020 ($MILLION)   
TABLE 58 SPAIN: LEUKEMIA DRUGS – PIPELINE MARKET REVENUE, BY DRUGS, 2008 – 2020 ($MILLION)   
TABLE 59 JAPAN: LEUKEMIA DRUGS MARKET REVENUE, BY DRUGS/REGIMENS, 2008 – 2020 ($MILLION)   
TABLE 60 JAPAN: LEUKEMIA DRUGS – PIPELINE MARKET REVENUE, BY DRUGS, 2008 – 2020 ($MILLION)   
TABLE 61 COLLABORATIONS/PARTNERSHIPS/AGREEMENTS/JOINT VENTURES   
TABLE 62 NEW PRODUCTS LAUNCH, 2008 – 2011   
TABLE 63 EXPANSIONS/NEW FACILITY/INVESTMENTS, 2011   
TABLE 64 FDA APPROVALS, 2008 – 2011   
TABLE 65 PHASE III CLINICAL TRIALS, 2008 – 2011   
TABLE 66 NDA, BLA & MARKETING APPLICATIONS, 2008 – 2011   
TABLE 67 AMBIT BIOSCIENCES: PRODUCT PIPELINE   
TABLE 68 ARIAD PHARMACEUTICALS: TOTAL REVENUE & R&D EXPENSES, 2008 – 2010 ($MILLION)   
TABLE 69 ARIAD PHARMACEUTICALS: PRODUCT PORTFOLIO   
TABLE 70 BIOGEN IDEC INC: TOTAL REVENUE & R&D EXPENSES, 2008 – 2010 ($MILLION)   
TABLE 71 BIOGEN IDEC INC: EXISTING PRODUCT & PIPELINE PRODUCT PORTFOLIO   
TABLE 72 BRISTOL-MYERS SQUIBB: TOTAL REVENUE & R&D EXPENSES, 2008 – 2010 ($MILLION)   
TABLE 73 BRISTOL-MYERS SQUIBB: PRODUCT PORTFOLIO   
TABLE 74 CELGENE CORPORATION: TOTAL REVENUE & R&D EXPENSES, 2008 – 2010 ($MILLION)   
TABLE 75 CELGENE CORPORATION: PRODUCT PIPELINE   
TABLE 76 CEPHALON INC: TOTAL REVENUE & R&D EXPENSES, 2008 – 2010 ($MILLION)   
TABLE 77 CEPHALON INC: PRODUCT PORTFOLIO   
TABLE 78 CLAVIS PHARMA ASA: TOTAL REVENUE & R&D EXPENSES, 2008 – 2010 ($MILLION)   
TABLE 79 CLAVIS PHARMA ASA: PRODUCT PORTFOLIO   
TABLE 80 EISAI CO. LTD: TOTAL REVENUE & R&D EXPENSES, 2008 – 2010 ($MILLION)   
TABLE 81 ISAI CO. LTD: PRODUCT PIPELINE   
TABLE 82 ERYTECH PHARMA: PRODUCT PIPELINE   
TABLE 83 GENMAB A/S: TOTAL REVENUE & R&D EXPENSES, 2008 – 2010 ($MILLION)   
TABLE 84 GENMAB A/S: EXISTING PRODUCT &PIPELINE PRODUCT PORTFOLIO   
TABLE 85 GENZYME CORPORATION: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION)   
TABLE 86 GENZYME CORPORATION: PRODUCT PORTFOLIO   
TABLE 87 GLAXOSMITHKLINE PLC: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION)   
TABLE 88 GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO   
TABLE 89 NOVARTIS INTERNATIONAL AG: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION)   
TABLE 90 NOVARTIS INTERNATIONAL AG: MARKET REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION)   
TABLE 91 PFIZER INC: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION)   
TABLE 92 PFIZER INC: MARKET REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION)   
TABLE 93 ROCHE HOLDING: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION)   
TABLE 94 ROCHE HOLDINGS: MARKET REVENUE, BY BUSINESS SEGMENTS, 2008 – 2010 ($MILLION)   
TABLE 95 ROCHE HOLDINGS: EXISTING & PIPELINE PRODUCT PORTFOLIO   
TABLE 96 SUNESIS PHARMACEUTICALS INC: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION)   
TABLE 97 SUNESIS PHARMACEUTICALS INC: PRODUCT PIPELINE   
TABLE 98 TALON THERAPEUTICS INC: TOTAL R&D EXPENSES, 2008 – 2010 ($MILLION)   
TABLE 99 TALON THERAPEUTICS INC: PIPELINE PRODUCT PORTFOLIO   
    
     
LIST OF FIGURES    
    
FIGURE 1 TOTAL LEUKEMIA MARKET, 2008 – 2020 ($MILLION)   
FIGURE 2 LEUKEMIA MARKET REVENUE, BY TYPES, 2008 – 2020 ($MILLION)   
FIGURE 3 LEUKEMIA POPULATION, BY COUNTRY, 2008 – 2020   
FIGURE 4 LEUKEMIA DEVELOPMENT & PROGRESSION RATE, BY AGE   
FIGURE 5 TYPES OF LEUKEMIA   
FIGURE 6 ACUTE LYMPHOCYTIC LEUKEMIA: MARKET SEGMENTATION, BY REGIMENS/DRUGS   
FIGURE 7 ACUTE LYMPHOCYTIC LEUKEMIA: EXISTING DRUGS MARKET SHARE, 2010 VS 2020   
FIGURE 8 ACUTE LYMPHOCYTIC LEUKEMIA: PIPELINE DRUGS MARKET SHARE, 2015 VS 2020   
FIGURE 9 CHRONIC LYMPHOCYTIC LEUKEMIA: MARKET SEGMENTATION, BY REGIMENS/DRUGS   
FIGURE 10 CHRONIC LYMPHOCYTIC LEUKEMIA: EXISTING & PIPELINE REGIMENS/DRUGS MARKET SHARE, 2010 VS 2020    FIGURE 11 ACUTE MYELOID LEUKEMIA: MARKET SEGMENTATION, BY REGIMENS/DRUGS   
FIGURE 12 ACUTE MYELOID LEUKEMIA: EXISTING REGIMENS/DRUGS MARKET SHARE, 2010 VS 2020   
FIGURE 13 ACUTE MYELOID LEUKEMIA: PIPELINE DRUGS MARKET SHARE, 2015 VS 2020   
FIGURE 14 CHRONIC MYELOID LEUKEMIA: MARKET SEGMENTATION, BY REGIMENS/DRUGS   
FIGURE 15 CHRONIC MYELOID LEUKEMIA: EXISTING REGIMENS/DRUGS MARKET SHARE, 2010 VS 2020   
FIGURE 16 CHRONIC MYELOID LEUKEMIA: PIPELINE DRUGS MARKET SHARE,  2015 VS 2020  
FIGURE 17 LEUKEMIA EXISTING REGIMENS/DRUGS MARKET SHARE, BY TYPES, 2010 VS 2020   
FIGURE 18 LEUKEMIA PIPELINE REGIMENS/DRUGS MARKET SHARE, BY TYPES, 2015 VS 2020   
FIGURE 19 U.S: INCIDENCE & MORTALITY CASES, 2008 – 2020   
FIGURE 20 U.S: EXISTING REGIMENS/DRUGS MARKET SHARE, BY TYPES, 2010 VS 2020 ($MILLION)   
FIGURE 21 U.S: PIPELINE REGIMENS/DRUGS MARKET SHARE, BY TYPES, 2015 VS 2020   
FIGURE 22 CANADA: INCIDENCE & MORTALITY CASES, 2008 – 2020   
FIGURE 23 CANADA: EXISTING REGIMENS/DRUGS MARKET SHARE, BY TYPES, 2010 & 2020   
FIGURE 24 CANADA: PIPELINE REGIMENS/DRUGS MARKET SHARE, BY TYPES, 2015 VS 2020   
FIGURE 25 U.K: INCIDENCE & MORTALITY CASES, 2008 – 2020   
FIGURE 26 U.K: EXISTING REGIMENS/DRUGS MARKET SHARE, BY TYPES, 2010 VS 2020   
FIGURE 27 U.K: PIPELINE REGIMENS/DRUGS MARKET SHARE, BY TYPES, 2015 VS 2020   
FIGURE 28 GERMANY: INCIDENCE & MORTALITY CASES, 2008 – 2020   
FIGURE 29 GERMANY: EXISTING REGIMENS/DRUGS MARKET SHARE, BY TYPES, 2010 & 2020   
FIGURE 30 GERMANY: PIPELINE REGIMENS/DRUGS MARKET SHARE, BY TYPES, 2015 VS 2020   
FIGURE 31 FRANCE: INCIDENCE & MORTALITY CASES, 2008 – 2020   
FIGURE 32 FRANCE: EXISTING REGIMENS/DRUGS MARKET SHARE, BY TYPES, 2010 VS 2020   
FIGURE 33 FRANCE: PIPELINE REGIMENS/DRUGS MARKET SHARE, BY TYPES, 2015 VS 2020   
FIGURE 34 ITALY: INCIDENCE & MORTALITY CASES, 2008 – 2020   
FIGURE 35 ITALY: EXISTING REGIMENS/DRUGS MARKET SHARE, BY TYPES, 2010 VS 2020   
FIGURE 36 ITALY: PIPELINE REGIMENS/DRUGS MARKET SHARE, BY TYPES, 2015 VS 2020   
FIGURE 37 SPAIN INCIDENCE & MORTALITY CASES, 2008 – 2020   
FIGURE 38 SPAIN EXISTING REGIMENS/DRUGS MARKET SHARE, BY TYPES, 2010 VS 2020   
FIGURE 39 SPAIN: PIPELINE REGIMENS/DRUGS MARKET SHARE, BY TYPES, 2015 – 2020   
FIGURE 40 JAPAN: INCIDENCE & MORTALITY CASES, 2008 – 2020   
FIGURE 41 JAPAN: EXISTING REGIMENS/DRUGS MARKET SHARE, BY TYPES, 2010 VS 2020   
FIGURE 42 JAPAN: PIPELINE REGIMENS/DRUGS MARKET SHARE, BY TYPES, 2015 VS 2020   
FIGURE 43 KEY GROWTH STRATEGIES (JANUARY 2008 – SEPTEMBER 2011)

Leukemia is part of the even broader group of diseases affecting the blood, bone marrow and lymphoid system, which are all known as hematological neoplasms. This type of cancer ia again sub-divided into acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML), hairy cell leukemia (HCL), T-cell prolymphocytic leukemia (T-PLL), large granular lymphocytic leukemia, and adult T-cell leukemia. Amongst these, AML, ALL, CLL and CML are the most common types of leukemia.

The risk of leukemia is closely associated with age. About 90% of all leukemia’s are diagnosed in adults. Incidence rate of leukemia is high in men and women over 66 years of age. Prevalence of chronic lymphocytic leukemia, acute myeloid leukemia, and chronic myeloid leukemia is very high in men and women between the ages of 75 and 84. Acute lymphocytic leukemia prevalence is high among one to four year old children and it is almost eight times more than the young adults aged between 20 and 24.

Leukemia diagnosed population, 2008 - 2020, (Thousands)

Source: Globocan

Leukemia is expected to be more prominent in the developed world due to genetic and environmental factor, and radiation exposure is the primary cause of all the types of leukemia. The incidence and mortality rates for leukemia are higher in whites than in people of the other racial and ethnic groups due to genetic factors. Generally, men are more likely to develop leukemia than women. It is estimated that males accounted for more than 57% of new cases of leukemia in 2010.